110 results about "Amphomycin" patented technology

The invention which belongs to the biotechnical field concretely relates to a brain targeted AmB polymer micelle administration system. The brain targeted AmB polymer micelle administration system is prepared by utilizing brain targeted head base Angiopep-2 modified polymer micelles extremely having a clinical application potential, and entrapping micromolecular hydrophobic drugs. The prepared brain targeted AmB polymer micelle administration system can effectively improve the uptaking of the hydrophobic drugs on brain capillary endothelial cells, and can effectively improve the accumulation amount of the drugs in the brain and the brain entrance efficiency of the drugs especially in a noninvasive intravenous injection mode; compared with present clinical preparations of the drugs, such as AmB for injection, the system of the invention has a substantially improved brain targeting efficiency; and the constructed polymer micelle administration system can obviously reduce the hemolyticity and the cytotoxicity of the AmB. The Angiopep-2 modified brain targeted AmB polymer micelle administration system of the invention can be used to promote the accumulation of hydrophobic drugs with low brain entrance efficiencies in the brain.

The invention provides a human blood fat (serum / plasma) quality management reference kit. The kit takes human serum (plasma) as a matrix; a human blood fat component (human apolipoprotein A1 antigen, apolipoprotein B antigen, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and the like), a stable system and an anticorrosion system are added to the matrix; the stable system is any combination of a surfactant of Triton series, Tween series, EDTA (ethylene diamine tetraacetic acid) series and the like, a polymer of polyvinyl alcohol series, polyvinylpyrrolidone series, polyethylene glycol series and the like, and a phosphate buffer solution; and the anticorrosion system is any combination of sodium azide, gentamicin, amphomycin and ProClin series. The invention further provides a preparation method of the kit. The kit is free from medium effect interference, is used for quality control and evaluation between the detection systems, and more really reflects actual quality conditions of human serum (plasma) samples, which are detected by detection systems.

The invention discloses a tissue sample preservative solution used for preserving tissue samples, such as fat, umbilical cords, placentas and the like, after collection and before separation. The tissue sample preservative solution mainly comprises following components: high-glucose DMEM dry-powder culture medium, sodium bicarbonate, DMSO, dexamethasone, insulin, penicillin, streptomycin, amphotericin and a heparin sodium injection. The high-glucose DMEM dry-powder culture medium and the sodium bicarbonate are used for maintaining osmotic equilibrium among cells inside and outside tissue, maintaining a pH value, maintaining a moistening situation of the tissue and providing nutritional components. The DMSO is a freeze-storage protective agent and can prevent freeze-injuries on the tissue samples. The dexamethasone can inhibit immunization and protect activity of stem cells in the tissue sample; the insulin can promote absorption and utilization of the tissue sample to glucose. The penicillin, the streptomycin and the amphotericin can prevent pollution from bacteria and moulds and can eliminate pollution which has occurred. The heparin sodium injection can prevent blood solidification in the tissue samples and increase a yield of the stem cells. The tissue sample preservative solution is simple in components, is low in cost, is convenient to use, can maintain activities of the stem cells in the tissue samples, such as fat, umbilical cords, placentas and the like, and can greatly reduce a time limit from collection to preparation of the tissue samples.

The invention relates to application of an effective part of a cockroach extract in preparing a drug for inhibiting fungus growth, and particularly relates to application of an effective part obtained by refining a crude cockroach extract through macroporous adsorption resin in the aspect of preparing a drug capable of resisting fungal infection. The effective part is refined from a fresh or dried Periplaneta americana L. polypide product through alcohol and water extraction, macroporous adsorption resin column chromatography and alcohol solvent elution, and has an obvious inhibition effect on the growth activity of candida albicans and a fungus growth inhibition capacity 80 times higher than that of fluconazole and 5-fluorocytosine and 800 times higher than that of amphotericin. The effective part of the cockroach extract can be prepared into forms, such as a hydrogel, a frothy gel, a cataplasm, freeze-dried powder, a water aqua, an aerosol, a suppository, a film, an external liniment, an ointment and the like, and is used for preparing pharmaceutical preparations for preventing and curing fungal infection, medical appliances and daily-use chemical products.

The present invention provides two new classes of polyene macrolide amide derivatives useful for treating or preventing fungal infections. The new polyene macrolide amide derivatives exhibit antifungal activity and are more water-soluble than conventional polyene antibiotics, such as amphotericin B and amphotericin B methyl ester.

The invention relates to a novel broad-spectrum antifungal medicine compound, a broad-spectrum antifungal medicine composition, an application of the compound or the composition in the preparation of a broad-spectrum antifungal medicine, and an application of the compound or the composition in the preparation of a medicine used for treating severe invasive infection (comprising Candida krusei) caused by invasive aspergillosis and / or Fluconazole-resistant Monilia and / or severe infection caused by Scedosporium and fusarium. The novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have extensive and strong antifungal activity and better dynamic property and safety. For deep mycotic infection, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition are better than the original voriconazole in the aspects of the antibiotic activity and the medicine resistance and is better than amphotericin B in the aspects of safety and effectiveness; and compared with the formerly applied voriconazole, Fluconazole, itraconazole and amphotericin B, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have reinforced medicine effect, less adverse reaction and good safety.

The invention provides a preserving fluid for preserving a virus sample at normal temperature for a long time. The preserving fluid is equipped whit nutrient substances such as salts, amino acids, glucose and the like required by virus survival, is added with virus protective agents such as polyvinylpyrrolidone, mannitol, trehalose and the like for protecting viruses, and is added with bacteriostatic agents such as amphotericin B, vancomycin and the like for inhibiting the growth of bacteria. The preserving fluid is safe and non-toxic, is simple to use, does not need cold chain preservation, can be used for transporting and preserving the virus sample at normal temperature for 3 days, and effectively solves the problems that the virus samples depend on cold chains in the sampling, transporting and preserving processes and the preservation time is short. The preserving fluid can maintain the primitiveness of the virus sample, is beneficial to comprehensive analysis and research of the virus sample, and is suitable for collection and transportation of epidemic virus samples.

The invention provides a culture medium for stomach cancer organs and a culture method. The culture medium comprises a basic culture medium 1640, specific addition factors and sterile water, wherein the mass ratio of the basic culture medium 1640 to the sterile water is 99:1; and the specific addition factors comprise B27 without vitamin A, N-acetylcysteine, EGFs (epidermal growth factors), Noggin, R-spondin 1, Wnt3a, CHIR99021, thiazovivin, Gastrin I, valproic acid, a penicillin and streptomycin mixed liquid, amphotericin B and Primocin. The culture medium can be adopted to culture the stomach cancer organs, morphology structures and gene characteristics of primary tissue can be maintained, the risk of microorganism pollution in stomach cancer culture can be effectively reduced, and the success rate and the survival rate of stomach cancer organ culture can be increased.

The invention relates to genitourinary tract microorganism cultivation and detect method thereof, in particular to a genitourinary tract ureaplasma urealyticum (Uu) and mycoplasma hominis (Mh) culture medium and a detect method thereof. The culture medium comprises a fluid medium and a solid medium which are combined when the medium is used for culturing, separating and differentiating mycoplasma. The formulation comprises essential elements such as tryptic soy broth, yeast extract, urea, arginine, L-cysteine, phenol red, HEPES liquid, calf (fetal calf) serum, manganese sulfate, vancomycin, amphotericin B, trimethoprim, polymyxin, penicillin, and the like, and thereby the nutrition for mycoplasma growth and the antibiotic combination for inhibiting undesired microbe growth are optimized, no millipore filter is needed for sample inoculation and subcultivation, and the mycoplasma grows quickly. The fluid medium can maintain and prolong the logarithmic phase and indicate the growth of the mycoplasma, and the solid medium can used for observing Uu and Mh bacterial colonies, which has large background reflectance, thereby being easy for differentiation and significantly increasing the sensibility and the specificity of genitourinary tract mycoplasma detect.

The invention provides a combination bacteriostat for selectively culturing HP (helicobacter pylori), the formula of the combination bacteriostat is that: 3-50mg / l of vancomycin, 5-10.0mg / l of nalidixic acid, 3-5.0mg / l of TMP, 1-2.0mg / l of amphotericin and 8-10mg / l of Nisin. The preparation method of the combination bacteriostat for selectively culturing the HP mainly comprises the following procedures of culture medium preparation and bacteria inoculation, culture and preservation. According to the combination bacteriostat containing the amphotericin B, the nalidixic acid, the vancomycin, the TMP and the Nisin, through the addition of the combination bacteriostat in a culture medium, not only can the pollution of mixed bacteria such as bacillus subtilis, gram positive cocci and mucedine be reduce, but also thymidine needed by the growth of the HP can be provided for the HP to inhibit the growth of the mixed bacteria.

The present invention relates to a marker gene for screening a drug inducing toxicity in human and a screening method using the same. More precisely, the invention relates to a microarray on which marker genes up-or down-regulated specifically by 16 drugs inducing pulmonary toxicity, teratogenicity, nephrotoxicity, cardiotoxicity or mutation (Methotrexate, Nitrofurantoin, Amiodarone, Carbamazepine, Valproic acid, Thalidomide, Cisplatin, Gentamycin, Amphotericine, Furylfuramide, N-nitroso-N-methylurea, methylmethanesulfonate, 4-nitroquinoline-N-oxide, 2-nitrofluorene, Doxorubicin and Daunorubicin) are integrated, a kit comprising the said microarray, and a screening method of a drug inducing toxicity in human using the same. The DNA microarray containing the marker gene of the present invention facilitates the construction of Toxtarget Array for screening a drug inducing toxicity in human using drug-specific genes, suggesting that this chip can be effectively used for monitoring drugs or chemicals carrying toxicity to human or determining risks thereof and also it can be used as a tool for examining mechanisms of toxicity / side effects caused by the drugs.

The present invention is the following Amphotericin B derivative:wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.

The invention relates to a method for screening high-yield amphotericin B streptomyces nodosus through high-throughput mutagenesis, a screened mutant strain, a recombinant engineering bacterium obtained from the mutant strain and an application thereof. The streptomyces nodosum ZJB2016050 which is a streptomyces nodosum strain capable of highly yielding amphotericin B is obtained by screening in the invention. The method disclosed by the invention has the beneficial effects that 1, the yield of amphotericin B can be conveniently, quickly and efficiently detected by a high-throughput amphotericin B high-yield strain screening method, and the mutation breeding and screening or verification efficiency of genetic engineering strains can be improved; 2, compared with an original strain N3, thestreptomyces nodosus N5 obtained by mutation breeding has the advantages that the amphotericin B yield is increased by 20%, and the streptomyces nodosus N5 can be used as the original strain of genetically engineered bacteria; 3, the yield of amphotericin B is respectively increased by overexpression of functional genes, wherein the yield of amphotericin B is increased by 20% by acetyl coenzyme Acarboxylase 1 (acc1), and 4, the kanamycin is low in price, wide in antibacterial spectrum and strong in bactericidal effect, is suitable for industrial use, has a relatively strong effect of improving the total yield of enterprises, and can reduce the cost by about 2000 yuan per tank by taking a 5L tank in a laboratory as a calculation result.

The invention belongs to the technical field of nano-drugs, and particularly relates to a double-targeting composite nano-system loaded with amphotericin B (AmpB) and beta-1,3-glucanase (Gls), and a preparation method and application of the double-targeting composite nano-system. According to the nano-system provided by the invention, Gls and AmpB are loaded by chitosan nanoparticles. The beta-1,3-glucanase modified chitosan nanoparticles are constructed for the first time, a double-targeting nano-system for fungal biofilm exopolysaccharide beta-1,3-glucan and internal thalli can be realized, and meanwhile, the beta-1,3-glucanase and the amphotericin B have a synergistic interaction effect, so that the removal capacity is improved. The double-loaded nano-system is used for damage removal of a fungal biofilm for the first time.

Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.

The invention discloses a novel rare earth-silver nanocluster antibacterial agent and a preparation method thereof. According to the invention, rare earth and silver elements with antibacterial properties are combined together to form the rare earth-containing silver nanocluster. A novel rare earth-silver nanocluster antibacterial agent is developed by utilizing the synergistic effect of the rare earth and silver elements. The antibacterial agent is a microcrystalline product, the microstructure of the antibacterial agent is analyzed by an X single crystal diffractometer, and a certain contribution can be made to the research of the structure-activity relationship of the rare earth element antibacterial mechanism. The inhibition zone method test shows that the antibacterial property of the nanocluster on common bacteria and fungi is equivalent to that of a common antibacterial agent gentamycin / amphotericin. The prepared rare earth-silver nanocluster antibacterial agent can be applied to various fields of antibacterial macromolecules, antibacterial coatings, antibacterial fabrics and the like, and then is used for manufacturing ceramic bathroom accessories, fresh air systems, indoor decoration coatings, clothes and other products.

The invention provides a drug for inhibiting enterovirus 71. Amphotericin B for clinically treating fungal infection is found to have the characteristic of inhibiting enterovirus 71; through a drug toxicity test, an inhibition test of the drug to viruses and a virus plaque formation test, the amphotericin B is found to obviously inhibit infection of the EV71 virus in an RD cell and a 293 cell; furthermore, the amphotericin B is found to play the virus infection resistance through influencing the adsorption of the EV71 virus. The drug provided by the invention is a novel drug for preventing and treating the enterovirus 71, and is higher in market value and good in clinical application prospect.

The invention discloses a placental tissue preservation liquid and a preparation method thereof. The placental tissue preservation liquid includes glucose injection, a serum replacement, gentamicin, amphotericin, trehalose and heparin lithium. The preparation method of the placental tissue preservation liquid includes adding the serum replacement, gentamicin, amphotericin B, magnesium ascorbyl phosphate hydrate, trehalose and heparin lithium into the glucose injection, wherein final concentrations of the ingredients are 0.5-2%, 800 U / mL, 15-30 ug / mL, 0.25-0.5 mg / mL, 0.6-3 mg / mL, and 20-40 U / mL. The placental tissue preservation liquid has clear composition and balanced nutrition, has no evident toxic and side effects on cells, can well maintain activity of in-vitro placental cells, and iseffective in preventing contamination of exogenous microorganisms introduced in the acquisition and transport steps.

The invention discloses a targeted drug composition for co-loading amphotericin B and adriamycin and an application of the targeted drug composition, and belongs to the fields of medicines and pharmaceutics, and provides a novel medical composition for treating leishmaniasis. Two medicines of amphotericin B and adriamycin having fluorescent tracing properties are used and loaded in a pharmaceutical carrier material which is favorable in biological safety and has pH responsiveness to form the medical composition, wherein the carrier material consists of hydrophilicity mannose residues which actively target macrophages, beta-cyclodextrin and hydrophobic propionyl. The medical composition is good in biological safety (cytotoxicity and hemolytic activity), and the stability, pH response medicine release properties, target capacity, and treatment efficiency are verified in a cell model. Besides, the synergistic reaction of the amphotericin B and the adriamycin is realized, so that the consumption of the medicine is greatly reduced, the side effect is reduced, the economic burden of patients is alleviated, and the targeted drug composition is hopeful to exert great effects on clinical application.

The invention discloses an application of a kind of small molecule compounds as an adjuvant in the preparation of antifungal drugs. After 51,520 small molecule compounds in a national compound sample bank are subjected to high-throughput screening, the result shows that when small molecule compounds as shown in a formula I to a formula X independently act on a candida albicans biological membrane, the inhibition ratio is almost zero, but when the small molecule compounds are used with conventional antifungal drugs such as amphotericin B, fluconazole or caspofungin, the remarkable synergism is achieved, the efficacy of the conventional antifungal drugs is improved by 30% or above, the use dosage of the conventional antifungal drugs is reduced, and the inhibiting effect of the antifungal drugs to drug resistance fungi is improved.

The present invention provides two new classes of polyene macrolide amide derivatives useful for treating or preventing fungal infections. The new polyene macrolide amide derivatives exhibit antifungal activity and are more water-soluble than conventional polyene antibiotics, such as amphotericin B and amphotericin B methyl ester.

The invention relates to an abalone cell culture medium and an abalone cell culture method. The abalone cell culture medium comprises an L-15 basal culture medium and mixed serum, wherein the mixed serum comprises fetal calf serum accounting for 15% of the volume of the abalone cell culture medium and inactivated abalone serum accounting for 5% of the volume of the abalone cell culture medium; thebasal culture medium comprises the following components: 100 * of a penicillin streptomycin mixed solution, gentamycin, amphotericin B, NaCl2, KCl, CaCl2, MgSO4 and MgCl2. According to the invention,polylysine coating improvement is performed on the surface of a six-hole cell culture plate, so that a complete culture medium formula for primary culture of haliotis discus hannai Ino blood cells isadjusted, and the haliotis discus hannai Ino blood cells having strong adherence capacity, stable state and good activity can be rapidly obtained in a short time. In addition, the abalone cell culture medium can also provide abalone cells for studies on nutrition, immunity, environmental toxicity, gene function analysis and the like.

The invention discloses an ester derivative of amphotericin B. The ester derivative of the amphotericin B widens the range of an existing antibacterial compound and can be used as a lead compound forcontinuous optimization. Meanwhile, the compound has good antibacterial activity, and the antibacterial activity of the compound is better than that of the amphotericin B; and compared with the amphotericin B, the compound has lower blood toxicity and cytotoxicity, and can reduce the toxic and side effects of the amphotericin on the human body while maintaining the antibacterial activity.

The invention relates to an amphotericin B nano composite containing amphotericin B, cholesteryl sodium sulfate, and cholesterol-PEG. According to the amphotericin B nano composite, cholesterol-PEG is used for modifying a nano composite containing amphotericin B and cholesteryl sodium sulfate, so that particle size and encapsulation efficiency are desirable, and excellent long circulation properties are achieved.

The invention provides a high-throughput screening method for anti-breast cancer drugs. The method is different from previous methods, and can provide accurate individualized treatment selection for cancer patients. The concentrations of amphotericin B and gentamicin in a tumor cell culture solution are controlled to improve the survival rate of tumor cells, effectively maintain the cell morphology and promote the absorption of nutrients by the tumor cells. The concentrations of insulin and a growth factor EGF in the tumor cell culture solution are controlled to improve the growth rate of thetumor cells and improve the cell activity, so a large number of highly active tumor cells can be obtained; and certain proportions of the insulin and the growth factor can be used to reduce the use amount of fetal calf serum, the fetal calf serum has a high price, so the reduction of the use amount facilitates resource saving; and the half-inhibitory concentration (IC50) error of the drug determined through drug screening using the cultured cells is small, so the detection frequency can be reduced.

The invention provides a composition and a method for killing drug-resistance aspergillus fumigatus, and belongs to the technical field of biology. The method for killing drug-resistance aspergillus fumigatus comprises the following steps: preparing a medicine; collecting a strain; preparing a spore suspension; performing a drug sensitivity test and a combining drug susceptibility test. By virtue of the steps, the minimum inhibitory concentration (MIC) of amphotericin B and cinnamyl aldehyde can be obtained, and the effect of killing drug-resistance aspergillus fumigatus can be achieved by utilizing the medicinal combinations of amphotericin B and cinnamyl aldehyde with different concentrations.

The invention discloses a pharmaceutical composition capable of killing drug-resistant aspergillus fumigatus and a method for killing drug-resistant aspergillus fumigatus, and belongs to the technical field of microorganism. The pharmaceutical composition is prepared from citral and an antifungal drug, wherein the antifungal drug comprises amphotericin B, voriconazole and itraconazole. The method for killing drug-resistant aspergillus fumigatus comprises the steps of preparing the composition, preparing a spore suspension, determining the drug MIC (Minimal Inhibitory Concentration) and carrying out a united drug sensitivity test. The pharmaceutical composition disclosed by the invention improves the antibacterial effect of the drug to the drug-resistant strain, reduces the toxic or side effects of the antifungal drug and is an ideal pharmaceutical composition for treating antifungal drug resistant aspergillus fumigatus infection.

The invention discloses a culture medium for helicobacter pylori as well as a preparation method and application of the culture medium, and belongs to the technical field of microorganisms. Specifically, the invention provides the culture medium for the helicobacter pylori, and every 1000 mL of the culture medium for the helicobacter pylori contains 3 to 10 g of agar, 5 to 10 g of cysteine, 0.3 to 0.8 mg of antibiotics, 3 to 10 g of soluble starch, 0.1 to 1 mL of lactic acid and 1 to 10 g of horse whole blood. Wherein the antibiotics are prepared from vancomycin, amphotericin B and polymyxin; in the antibiotics, the mass fraction of vancomycin is 30-60%, the mass fraction of amphotericin B is 30-60%, and the mass fraction of polymyxin is 30-60%. 30% to 80% of amphotericin B; and 0.1%-10% of polymyxin. The invention also provides a preparation method and application of the culture medium. The culture medium provided by the invention is suitable for quick growth and culture of helicobacter pylori, can effectively inhibit the growth of infectious microbes, reduces the use of antibiotics, and has great use value.